We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund. In this ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Newleos Therapeutics emerged Thursday with $93.5 million and a bundle of oral small molecules that it licensed from Roche, further demonstrating that the pharma-to-startup pipeline for CNS drugs is ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...

(Bloomberg) -- GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline. The British drugmaker boosted its 2031 ...

Incyte has a strong track record of revenue growth and a robust pipeline, targeting over 10 high-impact product launches by ...

sNDA accepted for Priority Review Datopotamab deruxtecan (AstraZeneca and Daiichi Sankyo) TROP2-directed DXd antibody drug conjugate Treatment of adults with locally advanced or metastatic ...